2024
Efficacy of long‐term risankizumab treatment for moderate‐to‐severe plaque psoriasis: Subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks (LIMMitless trial)
Strober B, Bachelez H, Crowley J, Elewski B, Gooderham M, Menter A, Strohal R, Chen M, Wu T, Zhan T, Photowala H, Armstrong A. Efficacy of long‐term risankizumab treatment for moderate‐to‐severe plaque psoriasis: Subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks (LIMMitless trial). Journal Of The European Academy Of Dermatology And Venereology 2024, 38: 864-872. PMID: 38179809, DOI: 10.1111/jdv.19748.Peer-Reviewed Original ResearchSevere plaque psoriasisLong-term efficacyPlaque psoriasisDisease manifestationsWeek 256Palmoplantar psoriasisSubgroup analysisDurable long-term efficacyOpen-label extension studyBaseline patient characteristicsProportion of patientsBody mass indexInflammatory skin diseaseMultiple clinical manifestationsPASI 90/100Psoriatic manifestationsRisankizumab treatmentBaseline characteristicsPatient characteristicsPsoriasis AreaSkin psoriasisMass indexClinical manifestationsArthritis statusPatient subgroups
2022
Utilization Trends and Impact of Secukinumab Treatment on Clinical Outcomes in Biologic-Naive Patients with Psoriasis in a US Real-World Setting
Strober B, Patil D, McLean R, Moore-Clingenpeel M, Guo N, Levi E, Lebwohl M. Utilization Trends and Impact of Secukinumab Treatment on Clinical Outcomes in Biologic-Naive Patients with Psoriasis in a US Real-World Setting. Dermatology And Therapy 2022, 12: 1351-1365. PMID: 35551619, PMCID: PMC9100304, DOI: 10.1007/s13555-022-00740-y.Peer-Reviewed Original ResearchBiologic-naive patientsInvestigator's Global AssessmentBody surface areaClinical outcomesUS real-world settingGlobal assessmentBiologic-experienced patientsEffectiveness of secukinumabMethodsThis observational studyPrior biologic useFirst-line therapyProportion of patientsSeverity Index scoreTreatment of psoriasisSimilar improvementsBiologic experiencePsoriasis RegistryResultsBetween 2015Secukinumab treatmentIGA scoreBiologic useClinical characteristicsPatient characteristicsPsoriasis AreaPatient cohortSex Differences in Moderate to Severe Psoriasis: Analysis of the Psoriasis Longitudinal Assessment and Registry
Goldburg S, Chen R, Langholff W, Lafferty K, Gooderham M, de Jong E, Strober B. Sex Differences in Moderate to Severe Psoriasis: Analysis of the Psoriasis Longitudinal Assessment and Registry. Journal Of Psoriasis And Psoriatic Arthritis 2022, 7: 132-139. PMID: 39296535, PMCID: PMC11361528, DOI: 10.1177/24755303221099848.Peer-Reviewed Original ResearchPsoriasis Longitudinal AssessmentDisease characteristicsDermatology Life Quality Index scoresDisease severitySystemic therapy-naïve patientsLife Quality Index scoresLongitudinal assessmentPhysician global assessmentSystemic steroid therapyLifestyle risk factorsTherapy-naïve patientsNonmelanoma skin cancerObjective disease severityBody surface areaHistory of anxietyQuality Index scoresQuality of lifeChi-square testPsoriasis characteristicsSteroid therapySevere psoriasisTherapy-naïveDisease durationBiologic-naïvePatient characteristics
2021
Signal Detection and Methodological Limitations in a Real-World Registry: Learnings from the Evaluation of Long-Term Safety Analyses in PSOLAR
Bissonnette R, Gottlieb A, Langley R, Leonardi C, Papp K, Pariser D, Uy J, Lafferty K, Langholff W, Fakharzadeh S, Berlin J, Brouwer E, Greenspan A, Strober B. Signal Detection and Methodological Limitations in a Real-World Registry: Learnings from the Evaluation of Long-Term Safety Analyses in PSOLAR. Drug Safety 2021, 44: 699-709. PMID: 34075572, PMCID: PMC8184557, DOI: 10.1007/s40264-021-01065-z.Peer-Reviewed Original ResearchConceptsMajor adverse cardiovascular eventsHazard ratioIncident usersObservational studyCox model regression analysisAdjusted hazard ratioAdverse cardiovascular eventsReal-world registryInternational observational studyLong-term observational studyDisease-based registryRelevant clinical dataMACE riskUstekinumab exposureCardiovascular eventsPatient characteristicsPsoriasis patientsTreatment cohortsMethodological limitationsComparator groupSafety registryClinical dataRegistry dataModel regression analysisConclusionOur resultsCharacteristics of Patients with Psoriasis Treated with Apremilast in the Corrona Psoriasis Registry
Gottlieb A, Merola J, Cirulli J, Williams C, Linowski G, Paris M, Litman H, Guo N, Emeanuru K, McLean R, Cronin A, Strober B. Characteristics of Patients with Psoriasis Treated with Apremilast in the Corrona Psoriasis Registry. Dermatology And Therapy 2021, 11: 253-263. PMID: 33475970, PMCID: PMC7858993, DOI: 10.1007/s13555-020-00479-4.Peer-Reviewed Original ResearchCorrona Psoriasis RegistryPsoriasis RegistryMost patientsPsoriatic arthritisRegistry enrollmentApremilast patientsPhase 3 clinical studiesReal-world observational studyConcomitant systemic treatmentPrior biologic exposureCharacteristics of patientsTreatment of psoriasisQuality of lifeHigh rateIndex dateObservational registrySevere psoriasisSystemic medicationsAdult patientsBiologic therapyPatient characteristicsSystemic treatmentBiologic exposureModerate diseasePsoriasis patients
2020
Efficacy of risankizumab in patients with moderate‐to‐severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa‐1 and UltIMMa‐2 studies
Strober B, Menter A, Leonardi C, Gordon K, Lambert J, Puig L, Photowala H, Longcore M, Zhan T, Foley P. Efficacy of risankizumab in patients with moderate‐to‐severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa‐1 and UltIMMa‐2 studies. Journal Of The European Academy Of Dermatology And Venereology 2020, 34: 2830-2838. PMID: 32320088, PMCID: PMC7818271, DOI: 10.1111/jdv.16521.Peer-Reviewed Original ResearchConceptsPrior biologic exposureSevere plaque psoriasisBaseline patient demographicsEfficacy of risankizumabPhase 3 trialDisease characteristicsWeek 16Logistic regression analysisPlaque psoriasisPatient demographicsBiologic exposureSuperior efficacyPlacebo-controlled phase 3 trialHumanized IgG monoclonal antibodyPrior biologic therapyProportion of patientsBody mass indexRegression analysisBaseline characteristicsBaseline demographicsBiologic therapyPsoriasis AreaWeek 52Patient characteristicsIgG monoclonal antibodies